{
  "docId": "019de076-9103-7399-8bed-9b1b1a8b182a",
  "docSlug": "93c36ca1f8977b3a70b566ce0ab54138",
  "documentTitle": "argenx SE | Investor Conference Presentation Deck | 27 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 27,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "roadmap",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a circular/arc layout to categorize assets into 'Immunology Innovation Program', 'Pipeline', and 'VYVGART Opportunity'.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-9103-7399-8bed-9b1b1a8b182a/16",
  "deckHref": "/decks/019de076-9103-7399-8bed-9b1b1a8b182a",
  "deckJsonHref": "/decks/019de076-9103-7399-8bed-9b1b1a8b182a.json",
  "deckAnchorHref": "/decks/019de076-9103-7399-8bed-9b1b1a8b182a#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Immunology Innovation Program arc",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca6c65b8-164c-4c34-a956-e564699623db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.25,
        "x": 0.15,
        "y": 0.3
      },
      "kind": "list",
      "text": "ARGX-109 (Anti-IL-6), ARGX-213 (Anti-FcRn), ARGX-121, ARGX-220",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02fe9b33-4444-44c5-9799-9bf4bcb95659",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.9,
        "w": 0.3,
        "x": 0.65,
        "y": 0.05
      },
      "kind": "list",
      "text": "VYVGART (efgartigimod alfa-fcab), VYVGART Hytrulo, $1.2B in gMG revenue in 2023, CIDP sBLA submitted, ITP MAA filed, 15 indications in development by 2025, PFS in development",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c7ea6c4-140f-4a1a-988c-07111259ac31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.45,
        "y": 0.25
      },
      "kind": "list",
      "text": "Empasiprubart (POC established in MMN, Trials in DGF and DM), ARGX-119 (Phase 1b/2a trials in CMS and ALS)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee3981eb-fafc-4e1a-90ef-1d9e1ed39e3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.35,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Pipeline Horizon",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d81de6be-8d65-42d6-9461-e1646dbb9960",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "roadmap",
      "slug": null,
      "matchId": "30c3ece7-22a8-428b-88b6-c63c629cc785",
      "evidence": "Visual progression of drug development stages from early research to commercialized products.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 15,
      "beatId": "9b26e95b-08d2-43e3-9516-c1a147c99880",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "The Breakthrough",
      "beatSlug": "rags-to-riches-the-breakthrough",
      "evidence": "Pipeline horizon and potential for transformation",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 15,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "febbca6c-7f97-4066-8898-43ab685a76f2",
      "evidence": "Pipeline horizon and potential for transformation",
      "position": 1,
      "objective": "Quick wins and big bets in pipeline development",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}